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Summary 
Human immunodeficiency virus (HIV) 1 transgenic mice expressing low or undetectable levels 
of viral mRNA in lymphoid tissue  were infected with the intracellular protozoan Toxoplasma 
gondii.  Exposure to this parasite resulted in an increase in HIV-1  transcripts in lymph nodes, 
spleens, and lungs during the acute phase of infection and in the central nervous system during 
the chronic stage of disease. In vivo and ex vivo experiments identified macrophages as a major 
source of the  induced  HIV-1  transcripts.  In  contrast,  T.  gondii  infection failed to stimulate 
HIV-1 transcription in tissues of two HIV-1 transgenic mouse strains harboring a HIV-1 provi- 
ral DNA in which the nuclear factor (NF) Kt3 binding moti~ from the viral long terminal re- 
peats had been replaced with a duplicated Moloney murine leukemia virus core enhancer. A 
role for NF-KB in the activation of the HIV-1 by T. gondii was also suggested by the simulta- 
neous induction of NF-KB binding activity and tumor necrosis factor c~ synthesis in transgenic 
mouse macrophages stimulated by exposure to parasite extracts. These results demonstrate the 
potential of an  opportunistic pathogen  to induce HIV-1  transcription in vivo and suggest a 
mechanism for the in vivo dissemination of HIV-1 by macrophages. 
T 
he progression towards AIDS in HIV-l-positive indi- 
viduals appears to be directly related to HIV-1 replica- 
tion and virus load in lymphoid tissues (1-3). In vitro stud- 
ies have demonstrated that activation of host immune cells 
(i.e., CD4 + T cells and macrophages) facilitates multiple steps 
of the virus life cycle (i.e., entry, integration, 1KNA synthe- 
sis, assembly, and/or release) in both primary and chroni- 
cally infected cells  (3).  Thus,  stimulation  of the  immune 
system may have an important influence on viral replication 
and progression of disease  in HIV-1 §  individuals.  HIV-1 
induction is regulated at the transcriptional level by cis-ele- 
ments in the  5'  LT1K of integrated HIV-1  proviral DNA 
(4, 5).  Several mechanisms by which the HIV-1 LTIK can 
be  activated  and  virus  replication  promoted  have  been 
demonstrated in vitro, a primary pathway involving the ac- 
tion of cytokines on infected host cells  (3,  6-12).  Events 
that induce cytokine expression in vivo such as concomi- 
tant infections might, therefore, enhance HIV-1 transcrip- 
tion affecting the levels of cell-free and cell-associated virus 
and possibly accelerate the progression to AIDS (13-16). 
Toxoplasma  gondii,  an  opportunistic  pathogen,  is  fre- 
quently associated with HIV-t infection, and is a common 
cause  of encephalitis in AIDS  patients  (17,  18).  Previous 
studies  have  indicated  that  infection with  this  protozoan 
parasite induces strong cell-mediated immune responses (19) 
and that live tachyzoites as well as tachyzoite extracts can 
directly trigger human/mouse monocytes or macrophages 
to produce a series ofmonokines (GM-CSF, TNF-0L, IL-1, 
IL-6, and IL-12; 19-23) among which are known enhanc- 
ers of HIV-1 expression in vitro (6-11). Indeed, recent ex- 
periments performed in our laboratories indicate that acti- 
vation  of human  primary  macrophages  with  T.  gondii 
promotes the replication of a monotropic strain of HIV-I 
in vitro (24). 
In  the  present study,  the  ability of T. gondii  to  trigger 
HIV-1  transcription  in  vivo was  investigated  in  recently 
developed transgenic mice incorporating the entire HIV-1 
proviral genome  (25).  HIV-1  transgenic  mice have been 
used in  the past  as models  of HIV-1  disease  (25-27)  but 
their application in defining the in vivo regulation of  HIV-1 
expression in  lymphoid cells  by another infectious agent 
has  not  been  reported.  The  results  presented here  show 
that infection with T. gondii enhances expression of HIV-1 
R.NAs in the spleens,  lymph nodes, and lungs during acute 
infection, and in brain tissue  during chronic disease.  The 
enhanced expression of HIV-1 transcripts appears to be lo- 
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of host rnonokines by the parasite. Our results demonstrate 
the  potential  of  an  opportunistic  pathogen  to  promote 
HIV-1  expression and provide an experimental model for 
the  development  of therapies  that  prevent  activation  of 
HIV-1  5'  LTR.  and  therefore  retrovirus  transcription  in 
vivo. 
Materials and Methods 
Derivation and Characterization of HIV-1  Transgenic Mice.  Trans- 
genic animal hosts were derived from FVB/N mouse (a routine 
inbred strain)  embryos (28) after the pronuclear microinjection of 
HIV-I  proviral DNA.  One  transgenic  mouse  line  (166)  con- 
tained the full-length, wild-type HIV-1 DNA; two independent 
derivatives (Hm28 and Hm54) of a second line, designated Molo- 
hey murine leukemia virus/HIV-l[Anuclear factor--KB]  (MLV/ 
HIV-I[ANF-KB]),  1 harbored  HIV-1  proviruses  in  which  the 
NF-K_13 binding motifs in the HIV-I LTR. were replaced with core 
enhancer sequences of MLV  (see Fig. 1). This replacement was 
originally designed to augment the very low levels of expression 
directed by the wild-type HIV-1 LTR in mouse cells or in previ- 
ously described transgenic mice. In the present study, transgenic 
animals  containing  the  MLV/HIV-I[ANF-KB]  proviral  DNA 
were used instead, as negative controls, to test the involvement of 
NF-KB  binding  sites  within  the  HIV-1  LTR.  on  T.  gondii- 
induced viral mR.NA expression. These mice were generated us- 
ing protocols described in detail elsewhere (29).  Briefly, PCIL- 
amplified MLV enhancer sequences were cloned into an Xbal site 
engineered by M13 mutagenesis at the position ofa NF-KB dele- 
tion  in  the  wild-type HIV-1  LTP,.  The  recombinant proviral 
DNA was then  assembled by the multiple ligation of genomic 
DNA fragments. 
The  three  transgenic lines stably transmitted their respective 
transgenes in Mendelian fashion (at 20-60 copies present at single 
integration sites) and expressed HIV-1  P,  NA in multiple tissues 
including secondary lymphoid organs  (25).  Each proviral DNA 
encoded the full complement of HIV-1  genes and directed the 
synthesis of three size  classes of viral mR.NAs corresponding to 
unspliced  (gag/pol),  singly  spliced  (vif,  vpr,  env)  and  multiply 
spliced (tat,  rev, nef)  HIV-1 transcripts (see Fig. 1). In contrast to 
the HIV-1  P,  NA patterns commonly associated with acutely in- 
fected human  lymphocytes but  reminiscent of a  R.ev-deficient 
phenotype (30),  HIV-1  P,  NA in mouse tissue  was often domi- 
nated  by  the  presence  of small molecular weight  (2-kb  class), 
multiply spliced transcripts. HIV-1  R.NA sizes  differed slightly 
between the wild-type HIV-1 transgenic line 166 and the MLV/ 
HIV-I[ANF-KB] recombinant lines (Hm28 and Hm54) because 
of the  presence  of MLV  enhancer sequences  in  the  LT1<  that 
elongated transcripts from the recombinant LTR by "~  bases 
(see Fig. 1 B). Experiments were conducted in heterozygous and 
homozygous line  166  mice,  whereas  only heterozygous Hm28 
and Hm54 mice were available for use since homozygous animals 
in the latter lines are nonviable. 
1Abbreviations used in this paper: H&E, hematoxyhn and eosin; HPRT, hy- 
poxanthine phosphoribosyltransferase;  MLV, Moloney routine leukemia 
virus; MLV/HIV-I[ANF-v,.B], recombinant HIV-1 containing a replace- 
ment of the two NF-KB binding sites from viral LTRs for a duplicated 
enhancer from MLV core; NF-KB, nuclear factor-KB; SAG-2, T. gondii 
surface antigen 2; STAg, soluble toxoplasma antigen. 
Experimental Infections with T. gondii.  HIV-1  and  MLV/HIV-1 
[~tNF-KB] transgenic mice as well as FVB/N nontransgenic con- 
trol animals were infected at 6-8-wk-old by intraperitoneal inoc- 
ulation with 20 cysts of ME-49 an avirulent strain of T, gondii. 
The cysts had been obtained from brains of donor mice infected 
at least 1 mo earlier as described previously (31). 
Histopathology.  At  8-10  (acute  stage)  or  50-70  d  (chronic 
stage)  postinfection animals were  killed by cervical dislocation. 
The  lungs  and brains of each  animal were  separated into  two 
lobes or halves, one of which was fixed in formalin for histopa- 
thology while the second was used for I<NA extraction (see be- 
low). After 24 h in formalin, the tissues were transferred to 70% 
ethanol before processing for paraftqn sections. The resulting slides 
were stained with hematoxylin and eosin (H&E) and the sections 
were evaluated microscopically as described previously (30). 
Cell Separation  Techniques.  Pooled spleen cells collected from 
mice  10  d  after infection with  T. gondii  were passed through  a 
column for T  cell enrichment (MTCC-100; R.&D Systems, Inc., 
Minneapolis, MN) or adhered in tissue culture--treated plastic for 
isolation of macrophages (21,  22).  FACS  |  analysis of spleen cells 
using anti-CD3 and anti-MAC1 mAbs (Becton Dickinson & Co., 
Immunocytometry Systems, SanJos6, CA) were used to verify the 
enrichment of T  cells or macrophages in the different splenocyte 
populations. Dead cells were excluded by propidium iodide staining. 
To prepare inflammatory macrophages, peritoneal exudate cells 
were obtained 5 d after i.p. injection of 1.5 ml of 3% thioglyco- 
late and plated at 2  ￿  106 cells/ml in 24-well flat-bottom plates 
(Costar Corp., Cambridge, MA). After 4 h of incubation (37~ 
5% CO2), the nonadherent cells were removed and the macro- 
phage-enriched monolayer was washed in warm medium (21, 22). 
In Vitro Stimulation  of Macrophage Monolayers.  A soluble extract 
of T. gondii tachyzoites (soluble toxoplasma antigen [STAg]) was 
obtained  by  sonication  and  centrifugation  of  tissue  culture- 
derived P,H  strain tachyzoites as previously described (31).  To 
measure monokine responses and/or induction of HIV-1 proviral 
transcription, STAg (5 txg/ml), Escherichia coli LPS (23; 100 ng/ml), 
or TNF-~ (100  U/rnl; Genzyme Corp., Cambridge, MA) were 
added in 1 ml of medium (DMEM,  10% FCS, 2 mM glutamine, 
100  U  ml/penicillin, 100  },g/ml streptomycin, 25  mM  Hepes, 
and 50  txM IS-ME) to monolayer wells in the presence of either 
control (GL-113 anti-13-galactosidase;  20 Ixg/ml) or anti-TNF-et 
(20  Ixg/ml)  mAbs  as  indicated.  The  supernatant  and  adherent 
cells were obtained 8-12 h after stimulation for measurement of 
TNF-ot or detection of actin or HIV-1 mRNAs, respectively. 
RNA  Preparation.  RNA was isolated from cells and tissues us- 
ing an adaptation of a published procedure (32). Total splenocytes 
(10v), fractionated spleen cell populations (2  ￿  10%  thioglyco- 
late-elicited macrophages (2  ￿  106 before adherence), or ~200 
mg of tissue (spleen, lung, or brain) were homogenized in 1 ml of 
ice-cold acid  guanidiniunl  thiocyanate  solution buffer  supple- 
mented with B-ME (0.7%). After addition of 0.1  ml of 2 M  so- 
chum acetate, pH 4.0,  1.0 ml of water-saturated phenol, and 0.2 ml 
of chloroform, the samples were mixed vigorously and left on ice 
for 15 nfin. RNA was recovered in the aqueous phase after cen- 
trifugation (10,000  rpm at 4~  and precipitated in isopropanol as 
previously described (32). The final RNA pellet was resuspended 
and stored frozen in water containing either 1 mM EDTA for re- 
verse transcriptase (RT)-PCR  or 0.2%  SDS  for Northern  blot 
analysis.  In some experiments, poly(A) I<NA was  isolated from 
total RNA samples by oligo-dT cellulose chromatography. 
Northern Blot Analysis of Proviral Transcripts.  RNA samples (20 
txg/lane)  were  fractionated by  electrophoresis through  agarose 
(1.25%) under denaturing conditions (2.2 M formaldehyde), blot- 
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nuclear microinjection of FVB/N embryos with either 
the wild-type  HIV-1 proviral DNA (line 166) or re- 
combinant  MLV/HIV-I[ANF-c,B]  proviral  DNA 
(lines Hm28  and Hm54)  in which  the  two  NF-r 
binding motit~ in the U3 region of the HIV-1 LTR 
between nucleotides  -129 and -74 (numbered rela- 
tive to the transcription start site) were deleted and re- 
placed with enhancer sequences from the MLV (Molo- 
ney MLV) according to a previously described cloning 
protocol.  (t3) Comparison  by  Northern  analysis of 
HIV-1  R.NAs extracted from eye lens (a site of high 
level constitutive  expression) of line 166 and HM28 
mice. The three species ofHIV-I RNA correspond in 
approximate size to genomic and spliced HIV-1 tran- 
scripts typically observed in infected human cells. RNA 
transcripts  from  MLV/HIV-I[ANF-KB]  mice  (line 
Hm28,  splenocytes)  are  larger  than  those  extracted 
from HIV-1 transgenic mice (line 166) because of the 
MLV insertion into the LTI~ region which extends the 
HIV-1 transcripts by ~200 bp. 
ted onto nylon membranes, UV cross-linked, and hybridized to a 
1.25-kbp  HindIII  Nef  cDNA  fragment  (26,  27).  Blots  were 
washed under stringent conditions (0.1 ￿  SSPE, 0.5% SDS, 65~ 
and visualized by phosphoimage analysis (model BAS2000;  Fuji 
Medical Systems,  Stamford,  CT).  Membranes were  stripped by 
boiling in 0.1 ￿  SSPE, 0.5% SDS and reprobed with a human ac- 
tin probe  (Life  Technologies, Baltimore, MD)  for measurement 
of a  housekeeping  transcript.  R.NA  molecular weight  markers 
(Life Technologies) were used to identify 18S and 28S RNA spe- 
cies after ethidium bromide staining of the agarose gels. 
Electrophoretic Mobility Shift Assay.  Nuclear extracts of perito- 
neal macrophages from  FVB/N  or HIV-1  transgenic mice un- 
stimulated or simulated with either LPS  (100 ng/ml), STAg (5 
I.~g/ml),  or TNF-(x (100 U/ml) were prepared as previously de- 
scribed (33) and assayed for the presence of NF-id3 binding activity 
by electrophoretic  mobility shift assay  (EMSA)  (34).  Two dou- 
ble-stranded oligonucleotide probes were employed: a palindro- 
mic KB probe (PD-KB; 35) or an HIV-l-derived NF-~d3 binding 
motif (HIV-1-KB; 4).  Approximately 0.4  p~g of nuclear extract 
was  used  in  each  binding reaction.  Antibodies directed  against 
NF-vd3 p65 protein, types C-20 or A (4 ~1 each; Santa Cruz Bio- 
technology Inc., Santa Cruz,  CA) were employed in the super- 
shift assays. 
RT-PCR.  1  Ixg of total RNA obtained from either lung or 
brain of ilafected mice was  reverse  transcribed using MLV  RT 
(GIBCO BRL, Gaithersburg, MD). The reaction mixture was then 
diluted 1:8 and 10 I~1 used for specific semi-quantitative amplifi- 
cation ofcytokine mlLNA using Taq DNA polymerase (Promega 
Corp., Madison, WI). Southern transfers of PCR products were 
subsequendy probed with internal cytokine-specific oligonucle- 
otides and visualized using the ECL chemiluminescent detection 
system  (Amersham International, Amersham, Bucks,  UK).  Nu- 
cleotide sequences for sense and antisense primers and probes for 
hypoxanthine  phosphoribosyltransferase  (HPR.T)  23,  IL-1  27, 
IL-6  33,  TNF-a 32,  GM-CSF 35,  and  T.  gondii-specific  gene 
surface antigen (SAG-2) [40] have been previously described (21, 
36) and the cycle numbers (indicated within the brackets) deter- 
mined experimentally. 
TNF-ot Assay.  TNF-o~ was  quantitated in  8-12-h  superna- 
tants of adherent peritoneal macrophage  cultures by means of a 
cytotoxicity  assay  using  TNF-sensitive L929  cells  and  murine 
rTNF-~x (Genzyme Corp.) as a standard (23). 
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Increased HIV- 1 mRNA  Expression  in  Tissues of Transgenic 
Mice Infected with T. gondii.  Infection  with  T.  gondii  ini- 
tially manifests  as  an acute phase  in which the  tachyzoites 
(the rapidly multiplying stage of the parasite)  are found in tis- 
sues accompanied by mononuclear inflammatory reactions 
leading to small necrotic loci. Parasite multiplication during 
this stage occurs preferentially in the liver, lungs, and lym- 
phoid tissues  (19,  37).  Paralleling  the tissue  tropism of the 
parasite,  expression  of discrete  HIV-l~pecific  RNAs was 
elevated in the lungs, spleens and lymph nodes (Fig.  2,  top 
and  Fig.  3,  left) of transgenic  mice  (line  166)  carrying  a 
complete copy of HIV-1  proviral DNA and analyzed dur- 
ing that period (10 d after T. gondii  infection).  HIV-1--spe- 
cific transcripts were identified on the basis  of  their size and 
comigration  with  HIV-1  RNA  extracted  from  produc- 
tively infected human  cells  (Fig.  3).  By comparison,  there 
was only a modest increase  in HIV-1 transcripts  in splenic 
extracts  from  a  second  infected  transgenic  mouse  line 
(Hm28) in which the NF-KB motifs in the LTR had been 
replaced  with  the  core  enhancer  element  from  MLV 
whereas  no  HIV-1  RNA  was  detected  in  lung  tissue  re- 
moved from the same animals  (Fig. 2).  Furthermore,  iden- 
tical  results  were  obtained  with  a  second  independently 
derived  transgenic  line  (Hm54)  containing  the  MLV  en- 
hancer  substitution  (designated  MLV/HIV-I[ANF-KB]) 
(data not shown). 
Histopathological  changes were  evident in  the  lungs  of 
acutely infected animals regardless of strain  (nontransgenic, 
HIV-1, or MLV/HIV-I[ANF-r,B] transgenic mice) and fea- 
tured  comparable  levels  of nodular  infiltrates  of lympho- 
cytes and macrophages (generally ~70  gtm in diameter)  as 
well as perivascular lymphocytic infiltrates  (Fig. 4, left). In- 
creases in actin RNA  in the lungs from all acutely infected 
animals  (Fig.  2,  top) probably  arise  from  these  infiltrating 
inflammatory  cells.  However,  it is  important  to note  that 
the  same  difference  in  actin  mRNA  levels  is  seen  in  the 
lungs of  control MLV/HIV-I[ANF-KB] transgenic mice with 
no increase in the appearance of viral transcripts.  RNA  ex- 
tracted from lungs of infected mice also contained elevated 
levels  (5-34-fold increases after normalization with HPRT 
Figure  2.  Transgenic mice were injected intraperi- 
toneally with 20 T. gondii cysts (0.5 ml brain homoge- 
nate)/mouse  or  brain homogenate alone (mock- 
infected animals). Animals were killed after 10 (acute 
phase, top) or 50 d  (chronic phase, bottom) and total 
RNA was prepared from different tissues. Acute infec- 
tion of HIV-1 transgenic mice (line 166 homozygous 
mice) with  T.  gondii resulted in  increased levels of 
HIV-l~pecific  transcripts in the lungs and spleens as 
detected by Northern blot analysis of total RNA (20 
p,g RNA/lane).  In contrast, acute infection of MLV/ 
HIV-1IANF-KBI (Hm28) transgenic  mice resulted 
only in a slight increase in HIV-1 transcripts associated 
with  spleen but  not lung. Northern  blot  analysis of 
brain extracts of chronicaUy  infected HIV-1 and MLV/ 
HIV-1  [ANF-KB] transgenic mice demonstrated in- 
creased HIV-1 transcription in HIV-1 (166) but not 
MLV/HIV-I[ANF-KB] (Hm28) transgenic mice. Each 
lane represents an individual animal. Hybridization  with 
an actin probe is shown to provide an internal standard 
with  a known  housekeeping gene. A repeat experi- 
ment with six additional mice gave similar results. 
1648  T. gondii Induces HIV-1 Transcription  In Vivo Figure 3.  (Left)  R.NA  was extracted from lymph nodes (cervical and axillary) or spleens of  line 166 mice during the acute phase of T. gondii infection, 
and Northern analysis was performed under identical conditions before and after purification of mRNA on an oligo-dT column. Control HIV-1 RNA 
was prepared from human PBMC 3 d after infection with virus derived from pNL4-3 transfections of CD4 + HeLa cells. (Right) Total spleen cells were 
collected from 166 HIV-1 transgenic mice, 10 d after infection with T. gondii, and enriched for either T lymphocytes  or macrophage-adherent cells. The 
expression of  HIV-1 transcripts in unfractionated  splenocytes, T cell-enriched fraction, and the adherent cell population was then compared by Northern 
blot analysis. The expression of CD3 marker in spleen cells was 30% and >90%, respectively, before and after T cell enrichment. The percentage of cells 
expressing the MAC-1 marker was 32% before and 82% after isolation of adherent population. The results shown are representative of  three separate ex- 
periments performed. 
mRNA)  of transcripts  for inflammation-associated  mono- 
kines (IL-1, IL-6, TNF-e~, and GM-CSF) and a tachyzoite- 
specific gene (SAG-2) (Fig. 4, right). 
After  the  development  of  immunity,  tachyzoites  are 
cleared from host tissues and necrotic foci regenerate.  The 
chronic phase  of infection ensues  and the parasite  charac- 
teristically  appears in the form ofbradyzoites contained within 
cysts found predominantly  in  the  central  nervous  system. 
Occasionally tachyzoites may escape from cysts and proba- 
bly boost the immune response that effectively controls the 
further dissemination  of the parasite  (19, 37). Elevations in 
tachyzoite mR.NA were detected in brains of infected con- 
trol  or transgenic  mice in the  chronic  phase  (30--50  d)  of 
infection  (Fig.  5,  right). In  contrast  to  the  same  tissues  in 
acutely infected animals (data not shown), brains of chroni- 
cally infected line 166 transgenic mice displayed marked in- 
creases inHIV-l-specific RNA  (Fig. 2, bottom). By contrast, 
HIV-1  transcripts  were  not  observed  in  brain  extracts  of 
line Hm28 (MLV/HIV-I[ANF-KB]) transgenic mice chron- 
ically infected with T. gondii.  Identical results were obtained 
with  the  second  fine  (Hm54)  of MLV/HIV-I[ANF-KB] 
animals  (data not shown).  Chronic disease in the brain tis- 
sues ofHIV-1 transgenic (as well as control) mice was char- 
acterized by intense  inflammatory infiltrates  and elevations 
(23-97-fold  after  normalization  with  HPP,.T  mP~NA)  of 
monokine  (IL-1,  IL-6,  TNF-ot,  and  GM-CSF)  mR.NAs 
(Fig.  5).  It is interesting  to note  that the  grade  of necrosis 
(1.3  -4-  1.1)  scored in brain sections of chronically infected 
166 mice was significantly greater than that (0.2  +  0.1) de- 
termined for infected nontransgenic FVB/N animals. 
Characterization  of HIV-1  RNA  and Identification  of Cellular 
Source of HIV-1  Transcripts.  HIV-l-related RNA  was de- 
1649  Gazzinelli et al. 
tected in spleens of uninfected HIV-1 transgenic mice, but 
it was smeared and of no discrete size (Fig, 2 and Fig. 3, left) 
(30).  This constitutively expressed HIV-1 RNA in lymphoid 
tissue  of HIV-1  transgenic  mice  had the  characteristics  of 
run-on  transcripts.  The  high  molecular  weight  HIV-1- 
related  nucleic  acid (Figs.  2  and 3) was RNA  based on its 
sensitivity  to RNase  and  on its  insensitivity  to DNase  di- 
gestion  (data  not  shown).  After  infection  with  T.  gondii, 
discrete HIV-1 transcripts appeared in the spleen and lymph 
nodes  but  some  high  molecular  weight  ILNA  persisted 
(Figs.  2 and 3). After the selection ofpoly(A) RNA, typical 
HIV-1 transcripts  (i.e.,  2.0, 4.3, and 9.2 kb) were enriched 
in cell extracts.  In addition,  the results presented  in Fig.  3 
(left) show that the discrete HIV-1 transcripts from T. gon- 
dii-infected mice comigrated with HIV-1 transcripts present 
in productively infected PBMC. 
Increases in tissue-associated HIV-1 RNA  after  T. gondii 
infection  arose  either  from the  activation  of HIV-1  tran- 
scription in resident cells or from the infiltration of lung or 
brain  by inflammatory  cells  expressing  HIV-1  RNA.  To 
investigate the cell source of HIV-1 transcription,  we frac- 
tionated  spleen  cells  from HIV-1  transgenic  mice  acutely 
infected with  T.  gondii.  Splenocytes  (36%  T  cells,  30%  B 
cells, and 32% macrophages)  harvested  10 d  after infection 
were separated into T  lymphocytes (>90% purity)  and ad- 
herent  cells  (,'-'82% macrophages)  and analyzed by FACS  | 
as  previously  described  (31).  As  shown  in  Fig.  3  (right), 
HIV-1 transcription in total splenocytes was detected in the 
macrophage-enriched  adherent  cell population  but not in 
the T  cell-enriched population. 
Induction  of HIV-1  Transcripts by T. gondii In  Vitro.  The 
ability ofmacrophages from HIV-1 transgenic mice to express Figure 4.  (Right)  Detection by RT-PCR ofrnRNAs for 
the cytokines  IL-1, IL-6, TNF-0e, and GM-CSF, as well as 
a  tachyzoite-specific gene  (SAG-2) in  lungs of HIV-1 
(166) and MLV/HIV-1  [ANF-KB] (Hm28) mice acutely 
infected with T. gondii (ME-49 strain). The  blot shows 
Southern hybridization  patterns of the PCR products with 
their respective internal oligonucleotide probes of RNA 
samples fi:om  lungs of individual control (noninfected ani- 
mals) or mice infected for 10 d. HPRT is shown as a control 
housekeeping gene. Three different animals were assayed 
in each group. Similar results were obtained in a second 
experiment. (Left) H&E stained sections of  lung tissues be- 
fore (upper  photomicrographs) and after infection (lower  micro- 
graphs) showing characteristic inflammatory infiltrates that 
were of similar intensity in  the  two  different transgenic 
mouse lines. ￿ 
HIV-1 RNA was investigated further in thioglycolate-elic- 
ited  populations  of peritoneal  macrophages,  activated  ex 
vivo with  known inducers  of I-/IV-1  LTR-directed  tran- 
scription.  Significantly,  whereas  a  soluble  extract  of ta- 
chyzoites  (STAg)  induced HIV-1  transcription  ex vivo in 
macrophages from line  166 transgenic mice containing the 
wild-type  HIV-1  LTR,  it had  no  effect  on  elicited  mac- 
rophages  from line  Hm28  (MLV/HIV-1 [ANF-KB]) mice 
(Fig. 6 A, left). As expected, LPS and TNF-c~ also induced 
expression  of  HIV-l-specific  mRNAs  in  inflammatory 
macrophages (Fig. 6 A,  right); STAg, under the conditions 
employed,  equalled  or  surpassed  these  agents  inducing  as 
much as fivefold (after normalization with actin RNA lev- 
els)  increases  in  HIV-1  RNAs.  Whereas  transcription  of 
HIV-1 RNA was not induced by LPS, STAg, or TNF-o~ in 
inflammatory macrophages from the two independent MLV/ 
HIV-I[ANF-~tB] transgenic lines  (Hm28 and Hm54),  ex- 
pression was confirmed in two additional HIV-1 transgenic 
mouse  lines  that  contain  the  wild-type  LTR  (designated 
AGag/Pol  [26, 27]  and AGag/Pol/Ne 0  (data not shown). 
Similar transcription results were obtained when bone mar- 
row-derived macrophages  obtained from the same MLV/ 
HIV-I[ANF-KB] or HIV-1  transgenic  mouse strains were 
stimulated  with  either  STAg,  LPS,  or  TNF--oe  (data  not 
shown). 
Role of TNF-ae and NF-KB in HIV-1 Expression Induced by 
T. gondii.  To examine mechanisms by which T. gondii could 
activate the HIV-1 LTR in the inflammatory macrophages 
from HIV-1 transgenic mice, we assayed culture media for 
the increased production of TNF-o~ after the activation  of 
macrophages. Transgenic macrophages were comparable to 
nontransgenic macrophages in their ability to produce and 
release TNF-o~ into the culture medium after STAg (Fig. 6 
A,  left) or  LPS  (data  not  shown)  treatment.  Comparable 
levels of TNF-o~ were produced by macrophages from ei- 
ther the wild-type HIV-1 or MLV/HIV-I[ANF-vd3] trans- 
genic lines after activation with different stimuli.  These re- 
sults  suggest that the inability of macrophages from MLV/ 
HIV-I[ANF-v,.B] transgenic  mice  to  express  HIV-1  tran- 
scripts is not due to a generalized defect in activation and/ 
or TNF-oe synthesis by these cells.  TNF-o~ is known to ac- 
tivate the HIV-1  LTR (7-11)  in a variety of different sys- 
tems. Therefore, we cultured macrophages from the HIV-1 
transgenic mice with  different stimuli  (i.e.,  STAg, LPS,  or 
1650  7". gondii Induces H1V-1 Transcription  In Vivo TNF-oe)  in  the  presence  of anti-TNF  mAb.  In vitro  neu- 
tralization  of TNF  blocked  the  activation  of HIV-1  tran- 
scription  by TNF-a  but  only partially blocked  STAg-  or 
LPS-induced  activation (Fig.  6  A,  right). 
The  ability of TNF-o~  to  stimulate  HIV-1  expression  is 
attributed,  at least in part, to the activation of NF-KB bind- 
ing  activity  (7).  To  further  analyze  this  question,  NF-cJ3 
induction in control and activated macrophages from FVB/ 
N  and the two types oftransgenic mice was measured in an 
EMSA  (34)  using  double-stranded  DNA  oligonucleotide 
probes  containing  either  a  NF-KB  consensus  binding  se- 
quence  (PD-KB;  Fig.  6  C,  right;  35)  or an HIV-l-derived 
NF-KB  binding  motif (HIV-1-KB;  4;  Fig.  6  B,  left).  In- 
creased  NF-~B  binding  activity  in  macrophages  was  ob- 
served when  cells were  stimulated with either STAg, LPS, 
or  TNF-e~.  The  identification  of NF-KB  binding  activity 
was confirmed in mobility shift assays by demonstrating the 
sensitivity  of the  binding  complex  to  supershifting  using 
commercial  antibodies  (types  C-20  or A)  directed  against 
the p65 component of NF-KB (Fig. 6 B). Under the condi- 
tions used, only the type A  antibody cross-reacted with the 
murine NF-r  component.  The nonreactive antibody  (C- 
20)  was  included  as  a  negative  control  for nonspecific  Ig 
binding.  Similar levels of LPS- or STAg-stimulated NF-KI3 
induction  were observed in inflammatory macrophages de- 
rived  from  nontransgenic  (Fig.  6,  B  and  C)  and  HIV-1 
transgenic mice (Fig. 6  C). Anti-TNF antibodies, while only 
partially  blocking  the  activation  of NF-KB  by  STAg  and 
LPS,  completely  inhibited  NF-KB  induction  by  TNF-c~ 
(Fig.  6  B). Thus,  the induction  of NF-rd3  and HIV-1 tran- 
scription  in macrophages from HIV-1  transgenic  mice ap- 
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Figure  5.  Detection of HPRT, IL-1, 
IL-6,  TNF-et,  GM-CSF,  and  SAG-2 
mRNAs  in  brain  extracts of  HIV-1 
transgenic (166)  mice acutely (10-d) or 
chronically (50-d) infected with  T. gon- 
dii  using methods  similar to  those de- 
scribed in  Fig. 4.  Similar results were 
obtained in a second experiment. Brain 
sections (stained with  H&E) of nonin- 
fected and infected transgenic (line 166) 
mice  are  shown  on  the  left: (top left) 
brain  section from  uninfected  mouse 
(￿  (top  right) section from acutely 
infected (10-d) mouse (X320) showing 
mild  inflammatory  infiltrate;  (middle) 
equivalent section from chronically in- 
fected  (50-d) mouse displaying intense 
inflammation; (bottom) higher magnifica- 
tion (￿  micrograph  of brain sec- 
tion  from same animal showing  three 
parasite cysts (upper right) and surround- 
ing inflammatory infiltrate. The intensi- 
fies of inflammatory infiltrates, expres- 
sion of cytokine mRNAs,  necrosis and 
cyst numbers were clearly augmented in 
mice  chronically infected  as  compared 
with those acutely infected  with  T. gondii. 
pears to share the same sensitivity to anti-TNF-oe inhibition 
(compare in Fig. 6, A  to B). 
Discussion 
In an attempt to develop an animal model to study HIV-1 
pathogenesis and the function of viral genes in vivo, several 
lines oftransgenic mice have been constructed (25--27). These 
animals provide a model for the postintegration  steps of the 
HIV-1 life cycle only. Any infectious virus progeny gener- 
ated in transgenic  mice harboring full-length  copies of the 
viral genome would  be unable  to  establish a  spreading in- 
fection  in  the  mouse  for several reasons including:  (a)  the 
failure  of HIV-1  to  adsorb  and  enter lymphocytes bearing 
mouse CD4  (38); and (b) the relative inefficiency, in mouse 
cells,  of the  HIV-1--encoded  Tat and  Rev proteins  to  di- 
rect levels of steady state RNA  and transport unspliced  and 
singly-spliced  viral  RNAs  from  the  nucleus  to  the  cyto- 
plasm, respectively (39-41). Expression directed by the wild- 
type LTR in mouse cells or previously described transgenic 
mice  is therefore  very low  (25-27).  Futhermore,  the  pat- 
tern of HIV-1 expression in mouse cells (39) or most tissues 
from transgenic  mice,  as monitored  by Northern  blot hy- 
bridization,  is  reminiscent  of a  "Rev  minus"  phenotype, 
i.e.,  predominantly  multiply spliced 2.0-kb  transcripts  and 
little  full-length  9.2-  and  4.0-kb  singly  spliced  mRNAs. 
Nevertheless,  depending  on the  degree  of proviral expres- 
sion,  tissue origin of the samples, and possibly the extent of 
viral mRNA  enrichment,  the profile observed in the North- 
ern  blot  may vary greatly.  As  shown  in  Fig.  1,  the  three 
classes of HIV-1  RNA  are clearly evident in samples puff- Figure 6.  (/t) (Left) HIV-1 RNA induced by T. gondii extracts in thioglycolate-elicited macrophages from HIV-1, MLV/HIV-I [ANF-KB] transgenic 
and nontransgenic littermates. Peritoneal macrophages were treated with tachyzoite extract (STAg, 5 I.tg/mt) and total RNA prepared 10 h  later. The 
samples (5 p~g RNA/lane) were analyzed for HIV-1 or actin-specific RNAs by Northern analysis (top). TNF-o~ levels were measured in cukure supema- 
tants from the same macrophages stimulated with STAg or left in media (bottom) using the L939 bioassay.  (Right) Thioglycolate-elicited macrophages 
were prepared as described above and exposed to either E. coli LPS (100  ng/ml, serotype 055:B5;  Sigma Chemical Co.), T. gondii extract (5 ~g/ml) or 
TNF-~x  (100  U/ml), in the presence of either control (GL-113 anti-~3-galactosidase;  20  ~g/ml) or anti-TNF-cr  (20  p~g/ml) mAbs as indicated. HIV-1 
transcripts were measured by Northern analysis and the intensities of the hybridization bands compared by densitometry and nornaalized with the signals 
given by actin RNA. (B) Nuclear extracts of  peritoneal macrophages from FVB/N mice stimulated in vitro with T. gondii extract as above were assayed 
for the presence of NF-KB binding activity in EMSAs as described in Materials and Methods. The HIV-1-KB (4) double-stranded oligonuceotide probe 
was used to detect the NF-c,B binding activity. Supershift antibodies (types C-20 or A) were obtained from Santa Cruz Biotechnology, Inc. and used ac- 
cording to the manufacturer's protocols. The reaction of the probe is shown in the presence (+) or absence (-) of the nuclear extract. (C) Comparison 
of  LPS- or STAg-induced NF-r,B activity in inflammatory macrophages derived from nontransgenic (FVB/N) versus HIV-1 transgenic (166)  mice using 
the double-stranded oligonucleotide probe, PD-KB (35). The experimental conditions were similar to those described in B. 
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study in this report. In contrast, expression directed by the 
wild-type LTR in most  other mouse tissues  is  extremely 
low and the RNA species observed are frequently limited 
to the fully spliced 2-kb class (Fig. 2). 
In the present study, we have shown that in vivo infec- 
tion with the opportunistic pathogen, T. gondii, leads to in- 
duction of HIV-1 mRNAs in tissues in which constitutive 
proviral expression is normally at the limit of detectability. 
The exposure of macrophages to parasite extracts in vitro 
enhances the level ofHIV-1 RNAs, arguing that these cells 
are likely to be a major target for parasite-induced proviral 
activation. It is interesting to note that, in addition to mul- 
tiply spliced low molecular weight transcripts, singly spliced 
4.2-  and  unspliced  9.0-kb  viral  mRNAs  are  evident  in 
some T. gondii-exposed tissues, suggestive evidence of par- 
tial Rev function. 
We  postulate  that  infection of HIV-1  transgenic  mice 
with T. gondii potentiates the expression of HIV-1 mRNA 
in  inflammatory cells  as  shown  ex vivo in  macrophages. 
During  Toxoplasma  infection,  infiltration  of tissues  (e.g., 
lungs and brain that normally display no or neglible levels 
of HIV-1 proviral expression) by inflammatory cells results 
in  the  synthesis  of measurable  levels  of HIV-l-specific 
RNAs. These HIV-1 transcripts are likely to represent pro- 
ducts of the cells migrating to the site of T. gondii infection 
rather than those preexisting in the tissue.  The latter con- 
cept  also  suggests  that  a  pathogen-induced  inflammatory 
response may play an important role in increasing HIV-1 
levels in specific tissue sites. Similar phenomena may occur 
during infection with other opportunistic pathogens, such 
as Mycobacterium tuberculosis (42-44) or M. avium (45) which 
also possess the ability to attract and activate macrophages 
into the infection site and therefore would promote HIV-1 
expression and viral spread in vivo. 
The data presented here also suggest that NF-K]3 induc- 
tion plays a  central role in the  activation of HIV-1  tran- 
scription in macrophages from HIV-1  transgenic mice by 
T.  gondii.  The failure  to  activate  HIV-1  transcription  in 
macrophages  from two  independent  MLV/HIV-I[ANF- 
KI3] transgenic mouse lines lacking NF-KB binding sites is 
consistent with the requirement of NF-KB activity for in 
vivo activation of the  HIV-1  LTR during infection with 
T. gondii. Furthermore, ex vivo activation experiments per- 
formed in the presence of anti-TNF antibodies suggest that 
both TNF-oL-dependent (7-11) and -independent mecha- 
nisms are involved in the HIV-1 LTR activation by T. gon- 
dii since neutralization of that cytokine caused only a minor 
inhibition in STAg-induced proviral transcription. The ex- 
istence  of TNF-independent  mechanisms  was  also  sug- 
gested by previous studies (46) indicating that direct expo- 
sure of a chronically infected monocytoid cell line to LPS 
or PMA results in an augmentation of HIV-1 replication in 
the absence of TNF-o~. 
Since toxoplasmosis can be associated with HIV-1 infec- 
tion (17,  18),  the results presented here imply that activa- 
tion of macrophages by tachyzoites (during acute infection 
and/or reactivation of chronic disease)  may augment viral 
gene expression and virus replication and lead to increased 
virus loads in HIV-l-seropositive individuals. However, to 
the best of our knowledge there is only one study suggest- 
ing that T. gondii m ay act as an HIV-1 cofactor. In the lat- 
ter report, increased congenital transmission of HIV-1 was 
observed in  children  of T.  gondii-infected  mothers  (47). 
Studies specifically evaluating HIV-1  progression in indi- 
viduals infected with the protozoan are necessary to vali- 
date this hypothetical disease interaction. 
A major limitation in studying the influence of coinfec- 
tions on the activation of HIV-1 in vivo, and therefore on 
AIDS  pathogenesis,  is  the  absence  of a  suitable  animal 
model.  The results presented here suggest that transgenic 
mice  containing  the  complete  wild-type  HIV-1  proviral 
DNA may serve as useful tools for investigating these phe- 
nomena as well as for testing effective therapies for the pre- 
vention or repression of HIV-1 transcription in vivo. Two 
important attributes of these transgenic mice are the induce- 
ability of HIV-1 gene expression in macrophages, and that 
the initiation and/or augmentation of viral transcription in 
macrophages appears to be under the control of the wild- 
type  HIV-1  LTR.  In  humans,  macrophages  represent  a 
major reservoir for HIV-1. Thus, the activation of HIV-1- 
infected macrophages  resulting in  transcription  of HIV-1 
genes and viral replication could be an important element 
affecting disease  progression  (48-51).  The  HIV-1  trans- 
genic mouse model described here should provide a useful 
tool for studying pathways responsible for HIV-1 induction 
in macrophages in vivo as well as for evaluating treatments 
that inhibit this potentially important mechanism of AIDS 
pathogenesis. 
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